Substances · Cathinone derivatives
α-PVP
- Preferred name
- α-PVP
- IUPAC name
- 1-phenyl-2-pyrrolidin-1-ylpentan-1-one
- Parent CAS number (reference)
- 14530-33-7
- Molecular formula
- C15H21NO
- Molecular weight
- 231.33 g/mol
- InChIKey
- YDIIDRWHPFMLGR-UHFFFAOYSA-N
- PubChem
- CID 11148955
- Source
- PubChem
- Verified synonyms & catalog abbreviations
-
alpha-PVP a-PVP aPVP alpha-pyrrolidinopentiophenone O-2387
Matching Listings in This Store's Catalog
Verified Neurochemical & Toxicological Intelligence
alpha-PVP (alpha-Pyrrolidinovalerophenone / alpha-Pyrrolidinopentiophenone)
Receptor Telemetry & Mechanism of Action
One of the most potent dopamine-norepinephrine reuptake inhibitors (NDRIs) characterized in vitro: high lipophilicity from the pyrrolidine ring drives rapid blood-brain barrier permeation, yielding DAT IC50 = 12.8–19.7 nM (Ki = 22.2 nM) and NET IC50 = 14.2–46 nM (Ki = 122 nM) with zero substrate release and negligible SERT inhibition (IC50 > 10,000–57,000 nM; DAT/SERT ratio > 781–2,900). Neurochemical and cardiovascular actions reflect primarily the (S)-enantiomer.
Biotransformation & Active Metabolites
Metabolized by hepatic CYP2B6, CYP2D6, CYP2C19, and CYP3A4 primarily to 1-phenyl-2-(pyrrolidin-1-yl)pentan-1-ol (OH-alpha-PVP) and 2''-oxo-alpha-PVP lactam. Human elimination half-life is ~2.1 hours, with clinical BP/HR peaking at 40 minutes.
Temporal Pharmacokinetics
Fierce, razor-sharp catecholaminergic rush marked by intense psychomotor stimulation, hyper-vigilance, compulsive repeated exposure cravings, strong peripheral vasoconstriction, and rapid escalation into agitation and paranoia.
- Onset 2–20 minutes oral
- Peak Window 1–2.5 hours (clinical cardiovascular peak at 40–60 minutes)
- Total Window 2–6 hours (clinical subjective duration 3–5 hours)
- Residual / Half-Life 4–12 hours of insomnia, adrenergic tension, anxiety, and crash; human elimination half-life is ~2.1 hours.
Extremely steep dose-response curve: threshold starts at 1 mg, common oral range is 10–25 mg, and exceeding 40–50 mg (or binge repeated exposure) carries a documented high rate of excited delirium, paranoid psychosis, hyperthermia (40–41 °C), rhabdomyolysis, acute renal failure, and cardiac arrest.
Quantitative Response Spectrum (Published Literature)
Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.
1 mg
Subtle increase in alertness, vigilance, and wakefulness.
Faint adrenergic crispness.
5–10 mg
Brisk mental energy, task focus, talkativeness, and modest mood lift.
Noticeable elevation in heart rate and blood pressure, dry mouth, and appetite suppression.
10–25 mg
Intense psychomotor rush, ego inflation, heightened libido, rapid thought acceleration, and strong urge to redose.
Marked tachycardia, systolic/diastolic hypertension peaking around 40–60 minutes, sweating, jaw clenching, and vasoconstriction.
25–40 mg (CAHMA strong: 25–50 mg)
Forced, jittery stimulation, restless tremors, hyper-vigilant anxiety, thought loops, and paranoid suspicion.
Severe peripheral vasoconstriction, muscle spasms, restless legs, bruxism, chest tightness, and hyperthermia.
40–50+ mg
Acute paranoid psychosis, terrifying hallucinations, violent agitation, and excited delirium.
Life-threatening hyperthermia (40–41 °C), rhabdomyolysis, acute kidney failure, myoclonus, seizures, cerebral hemorrhage, and myocardial infarction.
Interaction Matrix & Critical Contraindications
Critical Hazard — Never Combine
12.8 nM DAT and 14.2 nM NET blockade combined with MAO inhibition causes immediate, fatal hypertensive crisis, stroke, and hyperpyrexia.
Extreme synergistic tachycardia, vasospasm, hyperthermia, rhabdomyolysis, seizures, and cardiac arrest.
Tramadol triggers convulsions; opioids risk fatal respiratory depression once alpha-PVP's ~2.1-hour half-life clears.
Elevated Hazard — Avoid
Worsens dehydration, hyperthermia, and rhabdomyolysis while masking lethal depressant intoxication.
High probability of triggering acute psychotic delirium, extreme panic, and uncontrolled behavioral crises.
Caution / Receptor Attenuation
Slows hepatic oxidation of alpha-PVP, raising blood levels toward the >100 ug/L clinical intoxication and >300 ug/L overdose range.
Strongly provokes paranoid delusions and severe tachycardia.
Structural Isomer & Sibling Comparison
alpha-PVP is the sharpest, most noradrenergically intense benchmark of the pyrovalerone family (NET IC50 14.2 nM vs. 41.4 nM for alpha-PiHP and 60–935 nM for MDPHP). Compared to 6-carbon homologue alpha-PHP, alpha-PVP has a slightly shorter total window (2–6 h vs. 2–8 h) and shorter after-effects (4–12 h vs. up to 48 h), while hitting with a harsher cold adrenergic edge. Compared to NEP and Hexen, alpha-PVP is ~2.4–10x more potent at DAT/NET.
Physicochemical Stability & Storage
Form: White or off-white odorless crystalline powder or crystals as the hydrochloride salt (mp ~161.3 °C; freebase mp ~173 °C). · HCl salt is soluble in ethanol (~20 mg/mL), PBS (pH 7.2, ~10 mg/mL), DMSO (~10 mg/mL), and DMF (~3 mg/mL).
Store dry and tightly sealed away from light and heat.
Cross-Tolerance & Dependence Profile
Very high addiction liability due to rapid blood-brain barrier entry and ~2.1-hour half-life. Cross-tolerant with alpha-PHP, alpha-PiHP, MDPHP, NEP, and cocaine (3–7 days to halve, 1–2 weeks to baseline).
Chemical Architecture & Structural Profile
α-PVP (1-phenyl-2-pyrrolidin-1-ylpentan-1-one) is a reference compound belonging to the Cathinone derivatives class, characterized by the molecular formula C15H21NO and a molar mass of 231.33 g/mol. The parent molecule is indexed under CAS registry number 14530-33-7 and in the NCBI PubChem database as CID 11148955 (Standard InChIKey: YDIIDRWHPFMLGR-UHFFFAOYSA-N). This molecule shares its empirical formula (C15H21NO) with positional or structural isomers; unambiguous analytical identification requires matching the full IUPAC structure, CAS number (14530-33-7), and spectroscopic profile.
Citations
- PubChem — PubChem (2026-11-12)
Reference Toxicology & Safety Profile
In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), α-PVP is indexed within the Cathinone, Substituted cathinones, Substituted pyrrolidines structural group. Toxicological notes (PsychonautWiki): exact toxic threshold is unknown. Dependence liability (PsychonautWiki): highly addictive with a high potential for abuse. Documented cross-tolerance class: dopamine, stimulant. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.
Citations
- PubChem — PubChem (2026-11-12)
Analytical Use & Laboratory Notice
This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.
Citations
- EUDA / National Chemical & Controlled Substance Registry (IE) — National Regulatory Authority (IE) (2026-11-12)